The drugmaker’s U.S. expansion comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

When Hurricane Helene damaged western North Carolina in September, filling medical facilities with people who couldn't be ...

The VoxScan app allows users to interact with MRI and CT scans on everyday devices, aiming to improve patient outcomes and ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

Blue Cross Blue Shield is the best health insurance company in North Carolina. Its cheapest plan costs $458 per month before discounts. Blue Cross and Blue Shield of NC: Best overall Blue Cross and ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.

More than a month after Hurricane Helene devastated regions in the southeastern United States, some communities in western North Carolina's mountain towns and villages are still without water ...

The Lupus Foundation of America works to improve the quality of life for all people affected by lupus through programs of research, education, support and advocacy. Join our lupus registry, RAY, and ...

North Carolina has set an early voting record, the State Board of Elections announced Sunday. More than 4.2 million voters cast early ballots at in-person voting sites, officials said, adding that ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, ...